cefixime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 537 | 79350-37-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.10 mg/mL | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 41 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 29.33 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 47 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.24 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.31 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 28, 1989 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 54.10 | 17.87 | 83 | 4102 | 310604 | 63174233 |
| Gastroenteritis staphylococcal | 43.35 | 17.87 | 7 | 4178 | 73 | 63484764 |
| Secretion discharge | 32.64 | 17.87 | 16 | 4169 | 12215 | 63472622 |
| Panic attack | 31.11 | 17.87 | 19 | 4166 | 22312 | 63462525 |
| Clostridium difficile infection | 30.69 | 17.87 | 21 | 4164 | 29901 | 63454936 |
| Pulmonary congestion | 29.99 | 17.87 | 17 | 4168 | 17401 | 63467436 |
| Mucocutaneous candidiasis | 29.22 | 17.87 | 4 | 4181 | 11 | 63484826 |
| Toxic epidermal necrolysis | 28.91 | 17.87 | 19 | 4166 | 25315 | 63459522 |
| Biopsy colon abnormal | 27.51 | 17.87 | 5 | 4180 | 109 | 63484728 |
| Dysbiosis | 26.41 | 17.87 | 7 | 4178 | 899 | 63483938 |
| Gastrointestinal mucosa hyperaemia | 24.56 | 17.87 | 5 | 4180 | 201 | 63484636 |
| Movement disorder | 24.12 | 17.87 | 16 | 4169 | 21645 | 63463192 |
| Vaginal infection | 23.61 | 17.87 | 11 | 4174 | 7507 | 63477330 |
| Foetal growth restriction | 23.56 | 17.87 | 11 | 4174 | 7542 | 63477295 |
| Premature baby | 22.32 | 17.87 | 15 | 4170 | 20720 | 63464117 |
| Oligohydramnios | 22.14 | 17.87 | 10 | 4175 | 6356 | 63478481 |
| Stevens-Johnson syndrome | 22.07 | 17.87 | 16 | 4169 | 24934 | 63459903 |
| Candida test positive | 21.79 | 17.87 | 6 | 4179 | 890 | 63483947 |
| Malignant melanoma in situ | 21.56 | 17.87 | 6 | 4179 | 926 | 63483911 |
| Pseudomembranous colitis | 21.52 | 17.87 | 8 | 4177 | 3104 | 63481733 |
| Pulmonary mass | 21.16 | 17.87 | 15 | 4170 | 22581 | 63462256 |
| Atypical mycobacterial pneumonia | 19.65 | 17.87 | 3 | 4182 | 21 | 63484816 |
| Disorientation | 19.45 | 17.87 | 18 | 4167 | 39434 | 63445403 |
| Neutropenia | 18.92 | 17.87 | 38 | 4147 | 174967 | 63309870 |
| Vanishing bile duct syndrome | 18.26 | 17.87 | 5 | 4180 | 727 | 63484110 |
| Circumoral oedema | 18.12 | 17.87 | 4 | 4181 | 238 | 63484599 |
| Meniscus injury | 18.07 | 17.87 | 9 | 4176 | 7105 | 63477732 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Oral pustule | 42.57 | 22.73 | 8 | 2002 | 243 | 34954678 |
| Psoriatic arthropathy | 30.16 | 22.73 | 17 | 1993 | 19781 | 34935140 |
| Urticaria | 25.31 | 22.73 | 24 | 1986 | 62353 | 34892568 |
| Tendon pain | 22.90 | 22.73 | 8 | 2002 | 2987 | 34951934 |
| Acute generalised exanthematous pustulosis | 22.86 | 22.73 | 10 | 2000 | 6766 | 34948155 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Secretion discharge | 51.62 | 17.14 | 24 | 5692 | 14998 | 79723674 |
| Panic attack | 48.89 | 17.14 | 27 | 5689 | 24189 | 79714483 |
| Pulmonary congestion | 48.71 | 17.14 | 28 | 5688 | 27072 | 79711600 |
| Oral pustule | 39.90 | 17.14 | 8 | 5708 | 273 | 79738399 |
| Toxic epidermal necrolysis | 38.22 | 17.14 | 29 | 5687 | 44552 | 79694120 |
| Movement disorder | 38.19 | 17.14 | 24 | 5692 | 27235 | 79711437 |
| Drug hypersensitivity | 38.15 | 17.14 | 73 | 5643 | 298843 | 79439829 |
| Pulmonary mass | 36.81 | 17.14 | 24 | 5692 | 29010 | 79709662 |
| Clostridium difficile colitis | 34.49 | 17.14 | 24 | 5692 | 32259 | 79706413 |
| Acute generalised exanthematous pustulosis | 34.17 | 17.14 | 19 | 5697 | 17235 | 79721437 |
| Gastroenteritis staphylococcal | 33.34 | 17.14 | 7 | 5709 | 301 | 79738371 |
| Psoriatic arthropathy | 31.24 | 17.14 | 33 | 5683 | 77966 | 79660706 |
| Dysbiosis | 28.23 | 17.14 | 8 | 5708 | 1211 | 79737461 |
| Stevens-Johnson syndrome | 28.22 | 17.14 | 23 | 5693 | 39143 | 79699529 |
| Biopsy colon abnormal | 27.70 | 17.14 | 5 | 5711 | 96 | 79738576 |
| Pseudomembranous colitis | 26.27 | 17.14 | 11 | 5705 | 5363 | 79733309 |
| Agranulocytosis | 25.43 | 17.14 | 23 | 5693 | 45007 | 79693665 |
| Vaginal infection | 25.31 | 17.14 | 11 | 5705 | 5869 | 79732803 |
| Clostridium difficile infection | 22.54 | 17.14 | 21 | 5695 | 42664 | 79696008 |
| Pneumonia mycoplasmal | 22.45 | 17.14 | 7 | 5709 | 1471 | 79737201 |
| Mucocutaneous candidiasis | 21.35 | 17.14 | 4 | 5712 | 95 | 79738577 |
| Clostridium test positive | 21.21 | 17.14 | 10 | 5706 | 6444 | 79732228 |
| Urticaria | 20.89 | 17.14 | 43 | 5673 | 185158 | 79553514 |
| Febrile neutropenia | 20.81 | 17.14 | 49 | 5667 | 230950 | 79507722 |
| Drug reaction with eosinophilia and systemic symptoms | 20.26 | 17.14 | 24 | 5692 | 64220 | 79674452 |
| Candida test positive | 20.04 | 17.14 | 6 | 5710 | 1100 | 79737572 |
| Gastrointestinal mucosa hyperaemia | 19.88 | 17.14 | 5 | 5711 | 480 | 79738192 |
| Neutropenia | 19.68 | 17.14 | 55 | 5661 | 287655 | 79451017 |
| Tendon pain | 19.31 | 17.14 | 9 | 5707 | 5649 | 79733023 |
| Food protein-induced enterocolitis syndrome | 17.72 | 17.14 | 3 | 5713 | 39 | 79738633 |
| Pyrexia | 17.42 | 17.14 | 95 | 5621 | 678614 | 79060058 |
| Carnitine deficiency | 17.19 | 17.14 | 4 | 5712 | 277 | 79738395 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DD08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
| ATC | J01RA15 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
| ATC | J01RA16 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
| CHEBI has role | CHEBI:88188 | allergenic drug |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute otitis media | indication | 3110003 | |
| Gonorrhea | indication | 15628003 | DOID:7551 |
| Haemophilus Influenzae Acute Otitis Media | indication | 19021002 | |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Acute gonococcal urethritis | indication | 29864006 | |
| Bronchitis | indication | 32398004 | DOID:6132 |
| Streptococcal tonsillitis | indication | 41582007 | |
| Upper respiratory infection | indication | 54150009 | |
| Urinary tract infectious disease | indication | 68566005 | |
| Tonsillitis | indication | 90176007 | DOID:10456 |
| Acute bacterial bronchitis | indication | 233598009 | |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Streptococcus pyogenes infection | indication | 302809008 | |
| Infective otitis media | indication | 312218008 | |
| Pharyngitis | indication | 405737000 | DOID:2275 |
| Acute exacerbation of chronic bronchitis | indication | 425748003 | |
| Moraxella Catarrhalis Acute Otitis Media | indication | 703469002 | |
| Haemophilus Influenzae Bronchitis | indication | ||
| Haemophilus Influenzae Chronic Bronchitis | indication | ||
| Streptococcus Pneumoniae Chronic Bronchitis | indication | ||
| Streptococcus Pneumoniae Bronchitis | indication | ||
| Pneumonia due to Escherichia coli | off-label use | 51530003 | |
| Acute bacterial sinusitis | off-label use | 75498004 | |
| Haemophilus Parahaemolyticus Pneumonia | off-label use | ||
| Haemophilus Parainfluenzae Pneumonia | off-label use | ||
| Impaired renal function disorder | contraindication | 197663003 | |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.45 | acidic |
| pKa2 | 2.54 | acidic |
| pKa3 | 3.24 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 500MG/5ML | SUPRAX | LUPIN LTD | N202091 | Feb. 20, 2013 | RX | FOR SUSPENSION | ORAL | 9233112 | Dec. 14, 2028 | METHODS FOR TREATING BACTERIAL INFECTIONS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | IC50 | 4.24 | WOMBAT-PK | |||||
| 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Enzyme | IC50 | 5.92 | CHEMBL | |||||
| Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Streptokinase A | Enzyme | EC50 | 7.22 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019391 | VUID |
| N0000147544 | NUI |
| D00258 | KEGG_DRUG |
| 25033 | RXNORM |
| C0060400 | UMLSCUI |
| CHEBI:472657 | CHEBI |
| C04 | PDB_CHEM_ID |
| CHEMBL1541 | ChEMBL_ID |
| D020682 | MESH_DESCRIPTOR_UI |
| DB00671 | DRUGBANK_ID |
| 10898 | IUPHAR_LIGAND_ID |
| 97I1C92E55 | UNII |
| 5362065 | PUBCHEM_CID |
| 233747 | MMSL |
| 4374 | MMSL |
| d00072 | MMSL |
| 387536009 | SNOMEDCT_US |
| 96052006 | SNOMEDCT_US |
| 4019391 | VANDF |
| 125110-14-7 | SECONDARY_CAS_RN |
| 002737 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-766 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-766 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-767 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-767 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-201 | TABLET | 400 mg | ORAL | ANDA | 27 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-203 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 19 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-203 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 19 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-205 | TABLET, CHEWABLE | 200 mg | ORAL | ANDA | 19 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-205 | TABLET, CHEWABLE | 200 mg | ORAL | ANDA | 19 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-206 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-207 | POWDER, FOR SUSPENSION | 500 mg | ORAL | NDA | 27 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-208 | CAPSULE | 400 mg | ORAL | NDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-673 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 22 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-673 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 22 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-674 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 22 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-674 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 22 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54348-797 | CAPSULE | 400 mg | ORAL | ANDA | 27 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54348-797 | CAPSULE | 400 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-663 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-663 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-664 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-664 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-668 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 27 sections |
| Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-668 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 27 sections |
| Cefixime | Human Prescription Drug Label | 1 | 65862-751 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 25 sections |
| Cefixime | Human Prescription Drug Label | 1 | 65862-752 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 25 sections |
| CEFIXIME | Human Prescription Drug Label | 1 | 67877-584 | CAPSULE | 400 mg | ORAL | ANDA | 24 sections |
| CEFIXIME | Human Prescription Drug Label | 1 | 67877-584 | CAPSULE | 400 mg | ORAL | ANDA | 24 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-202 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
| SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-202 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |